Cytomx Therapeutics Stock Shares Owned By Institutions
| CTMX Stock | USD 0.87 0 0.34% |
CytomX Therapeutics fundamentals help investors to digest information that contributes to CytomX Therapeutics' financial success or failures. It also enables traders to predict the movement of CytomX Stock. The fundamental analysis module provides a way to measure CytomX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CytomX Therapeutics stock.
CytomX | Shares Owned By Institutions |
CytomX Therapeutics Company Shares Owned By Institutions Analysis
CytomX Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current CytomX Therapeutics Shares Owned By Institutions | 65.20 % |
Most of CytomX Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CytomX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CytomX Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for CytomX Therapeutics is extremely important. It helps to project a fair market value of CytomX Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since CytomX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytomX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytomX Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 65% of CytomX Therapeutics are shares owned by institutions. This is 46.05% higher than that of the Biotechnology sector and 37.26% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 66.28% lower than that of the firm.
CytomX Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.CytomX Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
CytomX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 376.7M | 302.3M | 277.8M | 105.2M | 114.4M | 108.7M | |
| Enterprise Value | 213.2M | 135.3M | 90.3M | (70.4M) | 111.2M | 105.6M |
CytomX Fundamentals
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.0233 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | (38.9 M) | ||||
| Shares Outstanding | 78.26 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 65.20 % | ||||
| Number Of Shares Shorted | 5.67 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 0.54 X | ||||
| Revenue | 101.21 M | ||||
| Gross Profit | 53.16 M | ||||
| EBITDA | (4.31 M) | ||||
| Net Income | (569 K) | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 13.97 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (56.03 M) | ||||
| Short Ratio | 9.58 X | ||||
| Earnings Per Share | 0.16 X | ||||
| Price To Earnings To Growth | (1.80) X | ||||
| Target Price | 5.29 | ||||
| Number Of Employees | 120 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 68.09 M | ||||
| Total Asset | 201.79 M | ||||
| Retained Earnings | (723.45 M) | ||||
| Working Capital | 27.02 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
| Net Asset | 201.79 M |
About CytomX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.